title: The effect of hyperinflation on respiratory muscle strength and efficiency in healthy subjects and patients with asthma.
abstract: We evaluated respiratory muscle strength and efficiency in 15 patients with asthma. There was a significant reduction in mean Plmax (89.3 +/- 4.7 versus 110.5 +/- 9.4 cm H2O, p less than 0.001) and efficiency (2.41 +/- 0.2 versus 4.2 +/- 0.6%, p less than 0.01). This reduction in strength and efficiency was seen only in the male patients. Following bronchodilator, there was a significant increase in Plmax (from 89.3 +/- 4.7 to 96.2 +/- 5.4 cm H2O, p less than 0.005) and efficiency (from 2.41 +/- 0.2 to 3.22 +/- 0.2%, p less than 0.001). There was no correlation between the change in strength and efficiency and the degree of improvement in FEV1 following bronchodilator. However, there was a significant correlation with the fall in lung volume. To determine whether hyperinflation would result in a reduction in respiratory muscle strength and efficiency, we induced a mean increase in end-expiratory lung volume of 0.66 L by applying continuous negative pressure around the chest in 10 healthy individuals. This was associated with a significant fall in Plmax (from 110.5 +/- 9.4 to 100.5 +/- 8.93 cm H2O, p less than 0.001) and efficiency (from 4.2 +/- 0.6 to 2.6 +/- 0.5%, p less than 0.005). The data suggest that the strength and efficiency of the respiratory muscles are reduced in asthmatic males but not in the females. The strength and efficiency of the respiratory muscles improve significantly following bronchodilator, and this improvement is related to reduction in lung volume.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Medicine, University of Colorado Health Sciences Center, Denver.
authors.forename: P
authors.initials: P
authors.lastname: Weiner
authors.forename: J
authors.initials: J
authors.lastname: Suo
authors.forename: E
authors.initials: E
authors.lastname: Fernandez
authors.forename: R M
authors.initials: RM
authors.lastname: Cherniack
mesh_terms: D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D000328:Adult; D001249:Asthma / Q000503:physiopathology*; D001993:Bronchodilator Agents / Q000627:therapeutic use; D005260:Female; D005652:Functional Residual Capacity; D006801:Humans; D008168:Lung / Q000503:physiopathology*; D008176:Lung Volume Measurements; D008297:Male; D008875:Middle Aged; D012123:Pulmonary Ventilation / Q000502:physiology; D012132:Respiratory Muscles / Q000502:physiology*; D012727:Sex Characteristics
chemical_list: D000318:Adrenergic beta-Agonists; D001993:Bronchodilator Agents